Thierry Burnouf

List of Publications by Year in descending order

259 papers	9,264 citations	44444 50 h-index	66518 82 g-index
271 all docs	271 docs citations	271 times ranked	9417 citing authors

#	Article	IF	Citations
1	Neuroprotective activity of a virusâ€safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models. Bioengineering and Translational Medicine, 2023, 8, .	3.9	5
2	Regenerative effect of expired platelet concentrates in human therapy: An update. Transfusion and Apheresis Science, 2022, , 103363.	0.5	2
3	Experience with <scp>COVID</scp>â€19 convalescent plasma provides vital guidance to future pandemics. Transfusion, 2022, 62, 681-684.	0.8	6
4	Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials, 2022, 280, 121311.	5.7	9
5	Near-infrared-driven photoablation of lung cancer tumors utilizing biomimetic platelet-polyethyleneimine-polypyrrole drug-free nanoparticles. Materials and Design, 2022, 215, 110481.	3.3	10
6	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clinical Microbiology Reviews, 2022, 35, e0020021.	5.7	64
7	Stepwise access to safe plasma proteins in resourceâ€constrained countries: Local production and pathways to fractionationâ€"Report of an International Society of Blood Transfusion Workshop. Vox Sanguinis, 2022, 117, 789-795.	0.7	7
8	International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the <scp>COVID</scp>â€19 pandemic. Vox Sanguinis, 2022, 117, 822-830.	0.7	17
9	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. European Journal of Cancer, 2022, 166, 208-218.	1.3	16
10	Platelet and extracellular vesicles in COVID-19 infection and its vaccines. Transfusion and Apheresis Science, 2022, 61, 103459.	0.5	7
11	The multifaceted role of platelets in mediating brain function. Blood, 2022, 140, 815-827.	0.6	20
12	Can the administration of platelet lysates to the brain help treat neurological disorders?. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	6
13	SARS-CoV-2 and cancer: the intriguing and informative cross-talk. Transfusion and Apheresis Science, 2022, 61, 103488.	0.5	5
14	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. Transfusion Medicine Reviews, 2022, 36, 125-132.	0.9	8
15	Use of COVIDâ€19 convalescent plasma in lowâ€and middleâ€income countries: a call for ethical principles and the assurance of quality and safety. Vox Sanguinis, 2021, 116, 13-14.	0.7	22
16	Guidance for the procurement of COVIDâ€19 convalescent plasma: differences between highâ€and lowâ€middleâ€income countries. Vox Sanguinis, 2021, 116, 18-35.	0.7	48
17	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. Platelets, 2021, 32, 226-237.	1.1	17
18	Prospective Therapeutic Applications of Platelet Extracellular Vesicles. Trends in Biotechnology, 2021, 39, 598-612.	4.9	79

#	Article	IF	Citations
19	Human platelet lysates for human cell propagation. Platelets, 2021, 32, 152-162.	1.1	17
20	Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses. Platelets, 2021, 32, 259-272.	1.1	18
21	Lessons learned in the collection of convalescent plasma during the COVIDâ€19 pandemic. Vox Sanguinis, 2021, 116, 872-879.	0.7	8
22	International Forum on the Collection and Use of COVIDâ€19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. Vox Sanguinis, 2021, 116, 1117-1135.	0.7	7
23	Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth media supplemented with 10% human platelet lysate. Cytotherapy, 2021, 23, S176-S177.	0.3	1
24	International Forum on the Collection and Use of COVIDâ€19 Convalescent Plasma: Responses. Vox Sanguinis, 2021, 116, e71-e120.	0.7	3
25	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. Brain, 2021, 144, 3142-3158.	3.7	21
26	Iridium Oxide Nanoparticleâ€“Protein Corona Neural Interfaces with Enhanced Electroactivity and Bioactivity Enable Electrically Manipulatable Physical and Chemical Neuronal Activation. Advanced Materials Interfaces, 2021, 8, 2100694.	1.9	4
27	Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps. Transfusion Clinique Et Biologique, 2021, 28, 225-227.	0.2	0
28	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 2021, 13, 1594.	1.5	31
29	Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate. Cytotherapy, 2021, 23, 902-907.	0.3	5
30	A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress. Biomedicine and Pharmacotherapy, 2021, 142, 112046.	2.5	12
31	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. ACS Biomaterials Science and Engineering, 2021, 7, 5823-5835.	2.6	17
32	Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer. Cancers, 2021, 13, 6076.	1.7	22
33	Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity. Blood Transfusion, 2021, 19, 467-478.	0.3	2
34	Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion. Trends in Biotechnology, 2020, 38, 13-23.	4.9	82
35	The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update. Current Nanoscience, 2020, 16, 413-424.	0.7	9
36	Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). Transfusion and Apheresis Science, 2020, 59, 102717.	0.5	28

#	Article	IF	Citations
37	Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?. Transfusion and Apheresis Science, 2020, 59, 102715.	0.5	8
38	Effect of cell culture biomaterials for completely xeno-free generation of human induced pluripotent stem cells. Biomaterials, 2020, 230, 119638.	5.7	31
39	Recovered plasma for fractionation: call for quality standards to end wastage. Vox Sanguinis, 2020, 115, 213-214.	0.7	3
40	Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer. Cancers, 2020, 12, 3394.	1.7	30
41	Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in lowâ€“ and middleâ€“ income countries. Africa Sanguine, 2020, 22, 5-7.	0.6	7
42	Sources of guidance on collection and use of COVID-19 convalescent plasma especially relevant to low- and middle- income countries. Africa Sanguine, 2020, 22, 18.	0.6	0
43	Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections. Npj Vaccines, 2020, 5, 103.	2.9	3
44	Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells. Cytotherapy, 2020, 22, 458-472.	0.3	18
45	Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges. Biomaterials, 2020, 260, 120163.	5.7	72
46	Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. Journal of Biomedical Science, 2020, 27, 45.	2.6	29
47	Points to consider in the preparation and transfusion of COVIDâ€19 convalescent plasma. Vox Sanguinis, 2020, 115, 485-487.	0.7	73
48	Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature. Frontiers in Oncology, 2020, 10, 599403.	1.3	0
49	ElÃ©ments Ã prendre en compte dans la prÃ©paration et la transfusion du plasma de personnes guÃ©ries du COVID-19 dans les pays Ã faibles ou moyens revenus. Africa Sanguine, 2020, 22, 8-10.	0.6	0
50	Biological and Rheological Properties of a Virally Inactivated Fibrin Glue (BiocolÂ®): Comparison to an Autologous Fibrin Glue. , 2020, , 71-78.		0
51	Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. Frontiers in Neurology, 2019, 10, 835.	1.1	44
52	A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots. Acta Biomaterialia, 2019, 96, 468-479.	4.1	34
53	Blood products: unmet needs for essential medicines. Lancet Haematology,the, 2019, 6, e598-e599.	2.2	15
54	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Journal of Biomedical Science, 2019, 26, 89.	2.6	20

#	Article	IF	Citations
55	Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past. Transfusion and Apheresis Science, 2019, 58, 102674.	0.5	22
56	The effect of human platelet lysate on the differentiation ability of human adipose-derived stem cells cultured on ECM-coated surfaces. Journal of Materials Chemistry B, 2019, 7, 7110-7119.	2.9	17
57	Improving haemophilia therapy in developing countries: virusâ€safe cryoprecipitate. Vox Sanguinis, 2019, 114, 635-636.	0.7	4
58	New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement. Transfusion and Apheresis Science, 2019, 58, 208-211.	0.5	3
59	A doubleâ€virallyâ€inactivated (Interceptâ€“solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells. Transfusion, 2019, 59, 2061-2073.	0.8	22
60	NanoBioAnalytical characterization of extracellular vesicles in 75-nm nanofiltered human plasma for transfusion: A tool to improve transfusion safety. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 101977.	1.7	12
61	Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Advanced Drug Delivery Reviews, 2019, 148, 146-180.	6.6	78
62	Human platelet lysate current standards and future developments. Transfusion, 2019, 59, 1407-1413.	0.8	61
63	Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation . International Journal of Nanomedicine, 2019, Volume 14, 8847-8859.	3.3	72
64	Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells. New Biotechnology, 2019, 49, 151-160.	2.4	17
65	Extracellular Microvesicles as New Industrial Therapeutic Frontiers. Trends in Biotechnology, 2019, 37, 707-729.	4.9	141
66	What can be learned in the snake antivenom field from the developments in human plasma derived products?. Toxicon, 2018, 146, 77-86.	0.8	3
67	Multifaceted regenerative lives of â€˜expiredâ€™ platelets. ISBT Science Series, 2018, 13, 323-330.	1.1	2
68	Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing <scp>RANKL</scp>/<scp>OPG</scp> ratio and depressing the <scp>TLR</scp>4/MyD88 signaling pathway. Journal of Pineal Research, 2018, 64, e12464.	3.4	51
69	International Forum on <scp>GMP</scp>â€grade human platelet lysate for cell propagation: summary. Vox Sanguinis, 2018, 113, 80-87.	0.7	45
70	International Forum on GMPâ€grade human platelet lysate for cell propagation. Vox Sanguinis, 2018, 113, e1-e25.	0.7	11
71	Circulatory-cell-mediated nanotherapeutic approaches in disease targeting. Drug Discovery Today, 2018, 23, 934-943.	3.2	24
72	Blood transfusion in subâ€Saharan Africa: understanding the missing gap and responding to present and future challenges. Vox Sanguinis, 2018, 113, 726-736.	0.7	43

#	Article	IF	Citations
73	Nanofiltration of extracellular vesicles from human plasma & their on-chip qualification and quantification with a NanoBioAnalytical platform. Meta Gene, 2018, 17, S7.	0.3	0
74	Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. Transfusion, 2018, 58, 2635-2644.	0.8	11
75	Principles of haemophilia care: The Asiaâ€Pacific perspective.. Haemophilia, 2018, 24, e245-e246.	1.0	1
76	Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. Frontiers in Medicine, 2018, 5, 33.	1.2	52
77	Bitter progress in the treatment of haemophilia A in low-income countries. Lancet Haematology,the, 2018, 5, e239.	2.2	8
78	The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1895-1900.	1.9	101
79	A Gelatin Hydrogel-Containing Nano-Organic PEIâ€“Ppy with a Photothermal Responsive Effect for Tissue Engineering Applications. Molecules, 2018, 23, 1256.	1.7	50
80	Fabrication of co-electrodeposition of plasma proteins/iridium oxide hybrid films. Ceramics International, 2018, 44, S117-S120.	2.3	3
81	Selfâ€Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy. Advanced Healthcare Materials, 2017, 6, 1700181.	3.9	36
82	Red blood cell transfusion and outcome in cancer. Transfusion and Apheresis Science, 2017, 56, 287-290.	0.5	23
83	Platelet transfusion in thrombocytopenic cancer patients: Sometimes justified but likely insidious. Transfusion and Apheresis Science, 2017, 56, 305-309.	0.5	5
84	Transfusion-related immunomodulation and cancer. Transfusion and Apheresis Science, 2017, 56, 336-340.	0.5	63
85	Convalescent Plasma and the Dose of Ebola Virus Antibodies. New England Journal of Medicine, 2017, 376, 1296-1297.	13.9	6
86	Catalase-Modulated Heterogeneous Fenton Reaction for Selective Cancer Cell Eradication: SnFe₂O₄ Nanocrystals as an Effective Reagent for Treating Lung Cancer Cells. ACS Applied Materials & Interfaces, 2017, 9, 1273-1279.	4.0	67
87	Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardization. ISBT Science Series, 2017, 12, 168-175.	1.1	8
88	The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 3236-3240.	1.3	35
89	Comparison of three human platelet lysates used as supplements for in vitro expansion of corneal endothelium cells. Transfusion and Apheresis Science, 2017, 56, 769-773.	0.5	18
90	Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease. Biomaterials, 2017, 142, 77-89.	5.7	41

#	Article	IF	Citations
91	Reflections on multiple strategies to reduce transfusion in cancer patients: A joint narrative. Transfusion and Apheresis Science, 2017, 56, 322-329.	0.5	6
92	The microbiome and transfusion in cancer patients. Transfusion and Apheresis Science, 2017, 56, 330-335.	0.5	10
93	The Current Global Status and Production Trends of Plasma Fractionation. The Korean Journal of Blood Transfusion, 2017, 28, 113-125.	0.1	1
94	Duration of red blood cell storage and inflammatory marker generation. Blood Transfusion, 2017, 15, 145-152.	0.3	29
95	Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfusion, 2017, 15, 512-521.	0.3	52
96	Plasma for fractionation: looking at its safety from a comprehensive angle. Transfusion, 2016, 56, 2900-2901.	0.8	0
97	Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. Transfusion and Apheresis Science, 2016, 54, 309-318.	0.5	31
98	Singleâ€use technology for solvent/detergent virus inactivation of industrial plasma products. Transfusion, 2016, 56, 1384-1393.	0.8	9
99	Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage. Vox Sanguinis, 2016, 111, 456-457.	0.7	1
100	Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion. Journal of Thrombosis and Haemostasis, 2016, 14, 2073-2074.	1.9	2
101	Current status and new developments in the production of plasma derivatives. ISBT Science Series, 2016, 11, 18-25.	1.1	5
102	Impact of Transfusion on Cancer Growth and Outcome. Cancer Growth and Metastasis, 2016, 9, CGM.S32797.	3.5	52
103	Convalescent Plasma for Ebola Virus Disease. New England Journal of Medicine, 2016, 374, 2498-2500.	13.9	16
104	Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion. Cytotherapy, 2016, 18, 911-924.	0.3	11
105	Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. Transfusion and Apheresis Science, 2016, 54, 168-169.	0.5	11
106	Commentary on technical specifications and safety requirements of serum eye drops: Keeping a close eye on the content in cytokines. Transfusion and Apheresis Science, 2016, 54, 170-171.	0.5	1
107	Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral Research, 2016, 130, 58-68.	1.9	54
108	Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials, 2016, 76, 371-387.	5.7	390

#	Article	IF	Citations
109	Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome. PLoS ONE, 2016, 11, e0153573.	1.1	14
110	Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia. PLoS ONE, 2016, 11, e0162973.	1.1	5
111	Blood cell-derived microparticles and nanoparticles: Multifaceted topics for research. Transfusion and Apheresis Science, 2015, 53, 106-107.	0.5	1
112	Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment. Transfusion, 2015, 55, 2433-2444.	0.8	29
113	TnBPâ‚Triton X-45 Treatment of Plasma for Transfusion Efficiently Inactivates Hepatitis C Virus. PLoS ONE, 2015, 10, e0117800.	1.1	11
114	A Call for Incorporating Social Research in the Global Struggle against Snakebite. PLoS Neglected Tropical Diseases, 2015, 9, e0003960.	1.3	34
115	Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing. Transfusion and Apheresis Science, 2015, 53, 95-98.	0.5	16
116	An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful?. Transfusion and Apheresis Science, 2015, 53, 137-145.	0.5	98
117	Blood cell-derived microvesicles with potential pathogenic roles in therapeutic blood components and specialized diagnostic tools in diseases. Transfusion and Apheresis Science, 2015, 53, 108-109.	0.5	7
118	Platelet microparticle: A sensitive physiological â€œfine tuningâ€•balancing factor in health and disease. Transfusion and Apheresis Science, 2015, 52, 12-18.	0.5	54
119	Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries. PLoS Neglected Tropical Diseases, 2015, 9, e0003501.	1.3	28
120	Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography. PLoS ONE, 2015, 10, e0122300.	1.1	17
121	Antiâ€inflammatory effects of platelet biomaterials in a macrophage cellular model. Vox Sanguinis, 2015, 109, 138-147.	0.7	24
122	Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. Transfusion and Apheresis Science, 2015, 53, 246-252.	0.5	22
123	The role of microparticles in inflammation and transfusion: A concise review. Transfusion and Apheresis Science, 2015, 53, 159-167.	0.5	72
124	Human plasmaâ€derived immunoglobulin G fractionated by an aqueous twoâ€phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable inÂvitro thrombogenic activity. Vox Sanguinis, 2015, 108, 169-177.	0.7	12
125	Platelet microparticles and cancer: An intimate cross-talk. Transfusion and Apheresis Science, 2015, 53, 168-172.	0.5	63
126	Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. New Biotechnology, 2015, 32, 199-211.	2.4	133

#	Article	IF	Citations
127	A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming. Bulletin of the World Health Organization, 2014, 92, 526-532.	1.5	60
128	Plateletâ€“Cancer Interactions. Seminars in Thrombosis and Hemostasis, 2014, 40, 296-305.	1.5	120
129	An approach to outreach patients with von Willebrand disease in Egypt by targeting women with heavy menstrual bleeding and/or bleeding symptoms. Haemophilia, 2014, 20, 238-243.	1.0	5
130	New approaches for manufacturing plasma derivatives. ISBT Science Series, 2014, 9, 160-167.	1.1	8
131	Dedicated removal of immunoglobulin (<scp>Ig</scp>)<scp>A</scp>, <scp>IgM</scp>, and <scp>F</scp>actor (<scp>F</scp>)<scp>XI</scp>/activated <scp>FXI</scp> from human plasma <scp>IgG</scp>. Transfusion, 2014, 54, 169-178.	0.8	18
132	Ebola virus convalescent blood products: Where we are now and where we may need to go. Transfusion and Apheresis Science, 2014, 51, 120-125.	0.5	60
133	Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals, 2014, 42, 260-270.	0.5	22
134	Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet, The, 2014, 384, 1347-1348.	6.3	28
135	â€œGo no Goâ€•in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!. Transfusion and Apheresis Science, 2014, 51, 113-119.	0.5	15
136	Platelet microparticles: Detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Reviews, 2014, 28, 155-166.	2.8	161
137	Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. Transfusion and Apheresis Science, 2014, 51, 107-112.	0.5	14
138	Standardized human platelet lysate supplement demonstrates to be an effective, serum-free, xeno-free, FBS replacement for culturing AT-/BM-/and UC-mesenchymal stem cells. Cytotherapy, 2014, 16, S85.	0.3	4
139	Platelets Effects on Tumor Growth. Seminars in Oncology, 2014, 41, 359-369.	0.8	89
140	Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment. Cancer Growth and Metastasis, 2014, 7, CGM.S11285.	3.5	164
141	Ex vivo Expansion of Bovine Corneal Endothelial Cells in Xeno-Free Medium Supplemented with Platelet Releasate. PLoS ONE, 2014, 9, e99145.	1.1	23
142	Dengue virus inactivation by minipool TnBP/Triton Xâ€45 treatment of plasma and cryoprecipitate. Vox Sanguinis, 2013, 104, 1-6.	0.7	14
143	Antimicrobial activity of platelet (PLT)â€poor plasma, PLTâ€rich plasma, PLT gel, and solvent/detergentâ€treated PLT lysate biomaterials against wound bacteria. Transfusion, 2013, 53, 138-146.	0.8	100
144	The plateletâ€“cancer loop. European Journal of Internal Medicine, 2013, 24, 393-400.	1.0	145

#	Article	IF	Citations
145	Platelet gels. ISBT Science Series, 2013, 8, 131-136.	1.1	6
146	Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model. Transfusion, 2013, 53, 1918-1928.	0.8	18
147	Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Reviews, 2013, 27, 77-89.	2.8	185
148	Treatment of Nonhealing Diabetic Lower Extremity Ulcers with Skin Graft and Autologous Platelet Gel: A Case Series. BioMed Research International, 2013, 2013, 1-9.	0.9	38
149	Human Platelet Antigen Alleles in 998 Taiwanese Blood Donors Determined by Sequence-Specific Primer Polymerase Chain Reaction. BioMed Research International, 2013, 2013, 1-5.	0.9	13
150	Natural scrub typhus antibody suppresses HIV CXCR4(X4) viruses. Gastroenterology Insights, 2013, 5, 8.	0.7	5
151	Single-Donor Allogeneic Platelet Fibrin Glue and Osteoconductive Scaffold in Orbital Floor Fracture Reconstruction. Annals of Plastic Surgery, 2013, 70, 370-374.	0.5	12
152	Purification of IgG and albumin from human plasma by aqueous two phase system fractionation. Biotechnology Progress, 2012, 28, 1005-1011.	1.3	18
153	Human blood-derived fibrin releasates: Composition and use for the culture of cell lines and human primary cells. Biologicals, 2012, 40, 21-30.	0.5	37
154	Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation. Biologicals, 2012, 40, 129-133.	0.5	18
155	Human platelet concentrates: a source of solvent/detergentâ€treated highly enriched brainâ€derived neurotrophic factor. Transfusion, 2012, 52, 1721-1728.	0.8	28
156	Plasma fractionation. ISBT Science Series, 2012, 7, 62-67.	1.1	3
157	Impact of solvent/detergent treatment of plasma on transfusionâ€relevant bacteria. Vox Sanguinis, 2012, 102, 277-284.	0.7	15
158	Recombinant plasma proteins. Vox Sanguinis, 2011, 100, 68-83.	0.7	42
159	A chromatographically purified human TGFâ€Î²1 fraction from virally inactivated platelet lysates. Vox Sanguinis, 2011, 101, 215-220.	0.7	13
160	Pharmacokinetic study of minipooled solvent/detergentâ€filtered cryoprecipitate factor VIII. Haemophilia, 2011, 17, e884-8.	1.0	14
161	Expansion of adipose tissue mesenchymal stromal progenitors in serumâ€free medium supplemented with virally inactivated allogeneic human platelet lysate. Transfusion, 2011, 51, 770-778.	0.8	71
162	Pathogen reduction technique for freshâ€frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems. Transfusion, 2011, 51, 446-447.	0.8	10

#	Article	IF	Citations
163	Plasma fractionation in Asia-Pacific: challenges and perspectives. ISBT Science Series, 2011, 6, 366-372.	1.1	7
164	Antivenoms for the treatment of snakebite envenomings: The road ahead. Biologicals, 2011, 39, 129-142.	0.5	125
165	Influence of ethanol on the release of growth factors in human blood-derived platelet gels. Biologicals, 2010, 38, 120-127.	0.5	14
166	A novel core fractionation process of human plasma by expanded bed adsorption chromatography. Analytical Biochemistry, 2010, 399, 102-109.	1.1	28
167	A virally inactivated plateletâ€derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets. Transfusion, 2010, 50, 1702-1711.	0.8	12
168	A Novel Technique Combining Platelet Gel, Skin Graft, and Fibrin Glue for Healing Recalcitrant Lower Extremity Ulcers. Dermatologic Surgery, 2010, 36, 453-460.	0.4	62
169	Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfusion Medicine, 2010, 20, 48-61.	0.5	53
170	Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sanguinis, 2010, 98, 12-28.	0.7	136
171	A novel virally inactivated human platelet lysate preparation rich in TGF-Î², EGF and IGF, and depleted of PDGF and VEGF. Biotechnology and Applied Biochemistry, 2010, 56, 151-160.	1.4	14
172	Plasma fractionation issues. Biologicals, 2009, 37, 88-93.	0.5	39
173	Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. Biologicals, 2009, 37, 306-312.	0.5	13
174	A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sanguinis, 2009, 97, 119-128.	0.7	38
175	New methods of plasma fractionation â€“ a presentation of the â€˜miniâ€poolâ€™ fractionation procedure developed in Egypt. ISBT Science Series, 2009, 4, 99-106.	1.1	10
176	Bloodâ€derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. ISBT Science Series, 2009, 4, 136-142.	1.1	28
177	Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents. Analytical Biochemistry, 2009, 389, 69-73.	1.1	5
178	In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 108, 56-61.	1.6	127
179	Quality of plasma and its fractionation. ISBT Science Series, 2008, 3, 148-151.	1.1	1
180	Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. Transfusion, 2008, 48, 1090-1098.	0.8	48

#	Article	IF	Citations
181	Quantitative assessment of the kinetics of growth factors release from platelet gel. Transfusion, 2008, 48, 2414-2420.	0.8	78
182	Properties of a concentrated minipool solventâ€detergent treated cryoprecipitate processed in singleâ€use bag systems. Haemophilia, 2008, 14, 956-962.	1.0	23
183	Current strategies aimed at prevention of viral contamination of coagulation factor concentrates. International Journal of Laboratory Hematology, 2008, 16, 398-399.	0.2	0
184	Cranioplasty Using Osteoconductive Scaffold and Platelet Glue. Journal of Trauma, 2008, 65, 1321-1327.	2.3	21
185	Biological and Biochemical Assays to Ensure the Quality and Safety of Plasma-Derived Products: Factor VIII Concentrates. Current Pharmaceutical Analysis, 2007, 3, 83-94.	0.3	3
186	Preparation and viral inactivation of cryoprecipitate in blood banks in resourceâ€limited countries. ISBT Science Series, 2007, 2, 121-128.	1.1	13
187	Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. Biologicals, 2007, 35, 329-334.	0.5	16
188	Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals, 2007, 35, 349-353.	0.5	16
189	Modern Plasma Fractionation. Transfusion Medicine Reviews, 2007, 21, 101-117.	0.9	230
190	Current strategies toÂprevent transmission ofÂprions byÂhuman plasma derivatives. Transfusion Clinique Et Biologique, 2006, 13, 320-328.	0.2	38
191	Global Forum of the World Federation of Hemophilia, September 26â€“27, 2005, Montreal, Quebec, Canada. Transfusion and Apheresis Science, 2006, 35, 151-172.	0.5	1
192	A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sanguinis, 2006, 91, 56-62.	0.7	34
193	A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion, 2006, 46, 2100-2108.	0.8	36
194	Place of Nanofiltration for Assuring Viral Safety of Biologicals. Current Nanoscience, 2005, 1, 189-201.	0.7	36
195	BLOOD-DERIVED, TISSUE ENGINEERING BIOMATERIALS. Biomedical Engineering - Applications, Basis and Communications, 2004, 16, 294-304.	0.3	1
196	Content and functional activity of von Willebrand factor in apheresis plasma. Vox Sanguinis, 2004, 87, 27-33.	0.7	12
197	Platelet-derived growth factor-AB and transforming growth factor-Î²1 in platelet gels activated by single-donor human thrombin. Transfusion, 2004, 44, 945-945.	0.8	24
198	Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals, 2004, 32, 115-128.	0.5	67

#	Article	IF	Citations
199	Assessment of complement activation during membrane-based plasmapheresis procedures. Journal of Clinical Apheresis, 2004, 19, 142-147.	0.7	15
200	WHO Expert Committee on Biological Standardization. Technical Report Series - World Health Organization, Geneva, 2004, 924, 1-232, backcover.	0.6	19
201	Chromatographic purification and properties of a therapeutic human protein C concentrate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 790, 199-207.	1.2	10
202	Nanofiltration of single plasma donations: feasibility study. Vox Sanguinis, 2003, 84, 111-119.	0.7	33
203	Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia, 2003, 9, 24-37.	1.0	185
204	Protein composition and activation markers in plasma collected by three apheresis procedures. Transfusion, 2003, 43, 1223-1230.	0.8	22
205	Residual cell content in plasma produced by three centrifugal apheresis procedures. Transfusion, 2003, 43, 1522-1526.	0.8	15
206	AIDS â€" Past and Future. New England Journal of Medicine, 2002, 346, 710-711.	13.9	1
207	Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. Journal of Proteomics, 2001, 49, 575-586.	2.4	108
208	Viral safety of plasma products â€“ do we have zero risk?. Transfusion and Apheresis Science, 2001, 24, 139.	0.5	0
209	Transmission of scrub typhus by blood transfusion?. Transfusion, 2001, 41, 1454-1454.	0.8	3
210	Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 599-607.	0.2	22
211	Purification of Human Ceruloplasmin as a By-Product of C1-Inhibitor.. Biological and Pharmaceutical Bulletin, 2000, 23, 1406-1409.	0.6	10
212	Virucidal heat-treatment of single plasma units: a potential approach for developing countries. Haemophilia, 2000, 6, 597-604.	1.0	18
213	Evaluation of a Fibrin Sealant Free of Bovine-Derived Components in an Experimental Vas Anastomosis Study. Urologia Internationalis, 2000, 65, 196-199.	0.6	8
214	Reducing the risk of infection from plasma products: specific preventative strategies. Blood Reviews, 2000, 14, 94-110.	2.8	184
215	Influence of formulation on jet nebulisation quality of Î±1 protease inhibitor. International Journal of Pharmaceutics, 1999, 178, 101-109.	2.6	6
216	Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma. Biomedical Applications, 1998, 715, 65-80.	1.7	21

#	Article	IF	Citations
217	Vasal Reanastomosis Using Fibrin Glue Combined with Sutures: Which Combination of Sutures in a Delayed Protocol?. European Urology, 1998, 33, 318-322.	0.9	10
218	Delayed Vasovasostomy: Experimental Study Using Fibrin Glue. European Urology, 1997, 31, 182-186.	0.9	11
219	Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use. Vox Sanguinis, 1997, 72, 133-143.	0.7	138
220	Jet nebulisation: Influence of dynamic conditions and nebuliser on nebulisation quality. Application to the Î± 1 protease inhibitor. International Journal of Pharmaceutics, 1997, 148, 93-101.	2.6	11
221	Evaluation of the effectiveness of different antifoams for an Î±1 PI solution. International Journal of Pharmaceutics, 1997, 156, 211-217.	2.6	3
222	Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use. Vox Sanguinis, 1997, 72, 133-143.	0.7	309
223	Development of an enzyme-linked immunosorbent assay for human plasma inter-Î±-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. Journal of Immunological Methods, 1996, 190, 61-70.	0.6	33
224	Value of Virus Filtration as a Method for Improving the Safety of Plasma Products. Vox Sanguinis, 1996, 70, 235-236.	0.7	18
225	Delayed vasal reanastomosis in rats: comparison of a microsurgical technique and a fibrin-glued procedure. British Journal of Urology, 1996, 78, 271-274.	0.1	15
226	Albumin batches and B19 parvovirus DNA. Transfusion, 1995, 35, 389-391.	0.8	28
227	Chromatography in plasma fractionation: benefits and future trends. Biomedical Applications, 1995, 664, 3-15.	1.7	77
228	New trends in plasma fractionation and plasma products. Vox Sanguinis, 1994, 67, 251-254.	0.7	1
229	Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates. Vox Sanguinis, 1994, 67, 132-138.	0.7	6
230	Strategy of Virus Removal / Inactivation of Plasma-Derived Products : Interest of Nanofiltration as a New Virus Elimination Method. , 1994, , 17-27.		3
231	Preparation and Properties of a Therapeutic Interâ€Alphaâ€Trypsin Inhibitor Concentrate from Human Plasma. Vox Sanguinis, 1994, 67, 329-336.	0.7	30
232	Nanofiltration, a New Specific Virus Elimination Method Applied to Highâ€Purity Factor IX and Factor XI Concentrates. Vox Sanguinis, 1994, 67, 132-138.	0.7	111
233	NEW TRENDS IN PLASMA FRACTIONATION AND PLASMA PRODUCTS TRENDS IN PLASMA FRACTIONATION. Vox Sanguinis, 1994, 67, 251-253.	0.7	6
234	Purification of Factor VIII/von Willebrand Factor from Human Plasma on Immobilized Lentil Lectin. Protein Expression and Purification, 1994, 5, 138-143.	0.6	4

#	Article	IF	Citations
235	Chromatographic removal of viruses from plasma derivatives. Developments in Biological Standardization, 1993, 81, 199-209.	0.2	13
236	A Pasteurized Therapeutic Plasma. Transfusion Medicine and Hemotherapy, 1992, 19, 91-94.	0.7	9
237	Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. Biologicals, 1992, 20, 91-100.	0.5	37
238	A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion, 1992, 32, 861-867.	0.8	38
239	Chromatographic Preparation of a Therapeutic Highly Purified von Willebrand Factor Concentrate from Human Cryoprecipitate. Vox Sanguinis, 1992, 62, 1-11.	0.7	58
240	A Highly Purified Factor VIII:c Concentrate Prepared from Cryoprecipitate by Ion-Exchange Chromatography. Vox Sanguinis, 1991, 60, 8-15.	0.7	1
241	A Highly Purified Factor VIII:c Concentrate Prepared from Cryoprecipitate by Ionâ€Exchange Chromatography. Vox Sanguinis, 1991, 60, 8-15.	0.7	72
242	Comparison of High Purity Factor IX Concentrates and a Prothrombin Complex Concentrate in a Canine Model of Thrombogenicity. Thrombosis and Haemostasis, 1991, 66, 609-613.	1.8	15
243	Parasitologic and Clinical Human Response to Immunoglobulin Administration in Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1991, 45, 297-308.	0.6	424
244	Biochemical and Physical Properties of a Solventâ€Detergentâ€Treated Fibrin Glue. Vox Sanguinis, 1990, 58, 77-84.	0.7	54
245	Biochemical and Physical Properties of a Solvent-Detergent-Treated Fibrin Glue. Vox Sanguinis, 1990, 58, 77-84.	0.7	34
246	Properties of a Highly Purified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional Chromatography. Vox Sanguinis, 1989, 57, 225-232.	0.7	3
247	Properties of a Highly Punified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional Chromatography. Vox Sanguinis, 1989, 57, 225-232.	0.7	74
248	Largeâ€Scale Production and Properties of a Solventâ€Detergentâ€Treated Factor IX Concentrate from Human Plasma. Vox Sanguinis, 1988, 55, 202-210.	0.7	35
249	Large-Scale Production and Properties of a Solvent-Detergent-Treated Factor IX Concentrate from Human Plasma. Vox Sanguinis, 1988, 55, 202-210.	0.7	24
250	Biochemical and Biological Properties of an Î±₁â€Antitrypsin Concentrate. Vox Sanguinis, 1987, 52, 291-297.	0.7	32
251	Chromosomal control of wheat gliadin: analysis by reversed-phase high-performance liquid chromatography. Theoretical and Applied Genetics, 1985, 70, 599-609.	1.8	26
252	Chromosomal control of glutenin subunits in aneuploid lines of wheat: analysis by reversed-phase high-performance liquid chromatography. Theoretical and Applied Genetics, 1985, 70, 610-619.	1.8	26

#	Article	IF	Citations
253	Reversed-phase high-performance liquid chromatography of reduced glutenin, a disulfide-bonded protein of wheat endosperm. Journal of Chromatography A, 1984, 299, 185-199.	1.8	44
254	Reversed-phase high-performance liquid chromatography of durum wheat gliadins: Relationships to durum wheat quality. Journal of Cereal Science, 1984, 2, 3-14.	1.8	33
255	Inheritance of glutenin subunits in F1 seeds of reciprocal crosses between European hexaploid wheat cultivars. Theoretical and Applied Genetics, 1983, 64, 103-107.	1.8	16
256	Glutenin subunits of genetically related European hexaploid wheat cultivars: Their relation to bread-making quality. Theoretical and Applied Genetics, 1980, 58, 107-111.	1.8	66
257	Strategies to Preclude Hepatitis C Virus Entry. , 0, , .		0
258	An overview of plasma fractionation. Annals of Blood, 0, 3, 33-33.	0.4	22
259	Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience. Annals of Blood, 0, 3, 22-22.	0.4	4